Trial reportCancer biology & therapy2013
Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.
Trial report in Cancer biology & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.PloS one · 2017Trial
- Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma.Cancer chemotherapy and pharmacology · 2023Article
- Lenalidomide (LENA) Hybrid Gold Complex Nanoparticles: Synthesis, Physicochemical Evaluation, and Perspectives in Nanomedicine.ACS omega · 2020Article
- Pancreatic cancer stroma: an update on therapeutic targeting strategies.Nature reviews. Gastroenterology & hepatology · 2020Review
- Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis.Cancers · 2019Review
- Article
- Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-κB.Oncotarget · 2018Article
- Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer.Surgery today · 2015Review
- Molecular Targeted Intervention for Pancreatic Cancer.Cancers · 2015Review
- A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.PloS one · 2015Article
- Trial Watch: Lenalidomide-based immunochemotherapy.Oncoimmunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the 6-mo overall survival, safety and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer.
methodsEligibility included: previously untreated metastatic adenocarcinoma of the pancreas with metastases incurable by surgery/radiation therapy; ECOG PS 0-2; adequate organ function; prophylactic anticoagulation for venous thromboembolic events (VTEs). Patients received lenalidomide 25 mg PO (days 1-21) and gemcitabine 1,000 mg/m ( 2) IV (days 1, 8 and 15) each 28-day cycle, with response evaluations every eight weeks.
resultsBetween 5/2009-4/2010, 72 patients (median age 64 years; 68% male; 42% ECOG PS 0) were enrolled in this multicenter, community-based study. Six-month OS was 37% (95% CI 26-48%). Median PFS and OS were 2.3 (95% CI 1.9-3.5) and 4.7 (95% CI 3.4-5.7) months, respectively. Eight partial responses (11%) were documented. Thirty-nine patients (54%) experienced thrombocytopenia (2 patients, 3% grade 4). Hematologic toxicities resulted in dose modifications for the majority of patients. Twenty patients (28%) developed VTEs during treatment.
conclusionsThe observed 6-month OS (37%) of lenalidomide with gemcitabine does not suggest improvement compared with historical results with gemcitabine alone. Toxicities and dose modifications likely limited dose intensity. Further development of this regimen in pancreas cancer is not recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.